PL EN


Preferencje help
Widoczny [Schowaj] Abstrakt
Liczba wyników
Tytuł artykułu

Concurrent determination of triclosan and flurbiprofen by high-performance liquid chromatography in simulated saliva and its application in dental nanogel formulation

Identyfikatory
Warianty tytułu
Języki publikacji
EN
Abstrakty
EN
A new high-performance liquid chromatographic (HPLC) method for determination of triclosan (TCS) and flurbiprofen (FBP) was successfully developed and validated at a single wavelength. The method involves extraction of the targeted drugs from nanogels and simulated saliva by using methanol as the extractant. The Agilent ZORBAX SB-C18 column (5 μm, 4.6 × 250 mm) was used for the chromatographic separations. The effects of various parameters were extensively evaluated and optimized. The optimal HPLC conditions were acetonitrile and 0.001 M citric acid (90:10, v/v) with a pH of 3.24 as the mobile phase, at a 0.3 mL/min flow rate under isocratic elution mode. Excellent sensitivity and specificity were achieved by ultraviolet (UV) detection at 242 nm. The method also demonstrated excellent linearity within the test range of 10–100 μg/mL with the correlation coefficient (R2) of 0.9998 for both the analytes. The practical applicability of the method was demonstrated by recovering TCS and FBP from nanogels and simulated saliva. The recovery of the analytes from the nanogels and the spiked simulated saliva samples was in the range of 97–98% and 96–99%, respectively, and their respective relative standard deviation (RSD) was less than 0.9% in both cases. System suitability parameters were found to be within acceptable limits. The method is simple, specific, and precise, and to the best of our knowledge, it is the first reported validated quantitative HPLC method for the concurrent determination of TCS and FBP in a pharmaceutical dental product. The method can be useful in the routine quality control analysis of dental formulations with TCS and FBP contents or products with a similar composition.
Rocznik
Strony
219--224
Opis fizyczny
Bibliogr. 35 poz.
Twórcy
autor
  • Discipline of Pharmaceutical Technology, School of Pharmaceutical Sciences, Universiti Sains Malaysia, 11800 USM, Penang, Malaysia
  • Department of Pharmaceutics and Pharmaceutical Microbiology, Faculty of Pharmaceutical Sciences, Usmanu Danfodiyo University, P.M.B. 2346, Sokoto,Nigeria
autor
  • Discipline of Pharmaceutical Technology, School of Pharmaceutical Sciences, Universiti Sains Malaysia, 11800 USM, Penang, Malaysia
autor
  • Discipline of Pharmaceutical Technology, School of Pharmaceutical Sciences, Universiti Sains Malaysia, 11800 USM, Penang, Malaysia
autor
  • Discipline of Pharmaceutical Technology, School of Pharmaceutical Sciences, Universiti Sains Malaysia, 11800 USM, Penang, Malaysia
Bibliografia
  • [1] Rosling B.; Dahlén G.; Volpe A.; FuruichiY.; Ramberg P.; LindheJ. J. Clin. Periodontol. 1997, 24, 881–887.
  • [2] Piñón-Segundo E.; Ganem-QuintanarA.; Alonso-Pérez V.; Quintanar-Guerrero D. Int. J. Pharm. 2005, 294, 217–232.
  • [3] Russell A. D. J. Antimicrob. Chemother. 2004, 53, 693–695.
  • [4] Bhargava H. N.; Leonard P. A. Am. J. Infect. Control 1996, 24, 209–218.
  • [5] ChenM.; LiuY.; LinC.; PonnusamyV.; JenJ. Anal. Chim. Acta 2013, 767, 81–87.
  • [6] Jones R. D.; Jampani H. B.; Newman J. L.; LeeA. S. Am. J. Infect. Control 2000, 28, 184–196.
  • [7] Rosling B.; Wannfors B.; Volpe A. R.; Furuichi Y.; Ramberg P.; Lindhe J. J. Clin. Periodontol. 1997, 24, 873–880.
  • [8] Steffen M. J.; Bhattacharya A.; Fernandes G.; Ebersole J. L. J. Dent. Res. 2006, 85 (7), 648–652.
  • [9] Joshi D.; Garg T.; Goyal A.; Rath G. Curr. Drug Deliv. 2015, 12, 564–577.
  • [10] Kesavalu L.; Bakthavatchalu V.; Rahman M. M.; Su J.; Raghu B.; Dawson D.; Fernandes G.; Ebersole J. L. Oral Microbiol. Immunol. 2007, 22, 232–239.
  • [11] Pihlstrom B. L.; Michalowicz B. S.; Johnson N. W. Lancet 2005, 366, 1809–1820.
  • [12] Kim J.; AmarS. Odontology 2006, 94, 10–21.
  • [13] Vyas S. P.; Sihorkar V.; MishraV. J. Clin. Pharm. Ther. 2000, 25, 21–42.
  • [14] Jain N.; Jain G. K.; Javed S.; Iqbal Z.; Talegaonkar S.; Ahmad F. J.; Khar R. K. Drug Discov. Today 2008, 13, 932–943.
  • [15] Heasman P. A.; Benn D. K.; Kelly P. J.; Seymour R. A.; Aitken D. J. Clin. Periodontol. 1993, 20, 457–464.
  • [16] Jeffcoat M. K.; Williams R. C.; Reddy M. S.; English R.; Goldhaber P. J. Periodontal Res. 1988, 23, 381–385.
  • [17] Suresh D. K.; Vandana K. L.; Mehta D. S. Indian J. Dent. Res. 2001, 12, 105–112.
  • [18] Akhlaq M.; Khan G.; Wahab A.; Khan A.; HussainA.; Nawaz A.; Abdelkader H. J. Adv. Pharm. Technol. Res. 2011, 2, 151.
  • [19] Chen M.; Zhu P.; Xu B.; Zhao R.; Qiao S.; Chen X.; Tang R.; Wu D.; Song L.; Wang S.; Xia Y.; Wang X. J. Anal. Toxicol. 2012, 36, 608–615.
  • [20] Mei C.; Li B.; Yin Q.; Jin J.; Xiong T.; He W.; Gao X.; Xu R.; Zhou P.; Zheng H.; Chen H. J. Chromatogr. B 2015, 993–994, 69–74.
  • [21] Kyung-Mi P.; Zhong-Gao G.; Chong-Kook K. J. Liq. Chromatogr. Relat. Technol. 1997, 20, 1849–1855.
  • [22] Piccoli A.; Fiori J.; Andrisano V.; Orioli M. Farmaco 2002, 57, 369–372.
  • [23] Yilmaz B.; Erdem A. F. J. Chromatogr. Sci. 2015, 53, 1443–1448.
  • [24] Askholt J.; Nielsen-Kudsk F. Acta Pharmacol. Toxicol. (Copenh). 1986, 59, 382–386.
  • [25] Hanif M.; Nazer N.; Chaurasiya V.; ZiaU. Trop. J. Pharm. Res. 2016, 15, 605–611.
  • [26] Liu T.; Wu D. Int. J. Cosmet. Sci. 2012, 34, 489–494.
  • [27] Madikizela L. M.; Muthwa S. F.; Chimuka L. South African J. Chem. 2014, 67, 143–150.
  • [28] Shen J. Y.; Chang M. S.; Yang S.; Wu G. J. J. Liq. Chromatogr. Relat. Technol. 2012, 35, 2280–2293.
  • [29] Li P.; Liu X.; Wang X. Acta Chromatogr. 2015, 27, 255–266.
  • [30] Marques M. R. C.; Loebenberg R.; Almukainzi M. Dissolution Technol. 2011, 18, 15–28.
  • [31] Illangakoon U. E.; Gill H.; ShearmanG. C.; Parhizkar M.; Mahalingam S.; Chatterton N. P.; Williams G. R. Int. J. Pharm. 2014, 477, 369–379.
  • [32] Aminu N.; Baboota S.; Pramod K.; Singh M.; Dang S.; Ansari S. H.; Sahni J. K.; AliJ. J. Nanoparticle Res. 2013, 15, 2075.
  • [33] International Conference on Harmonization (ICH), Validation of Analytical Procedures: Text and Methodology, Q2 (R1), 2005. http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q2_R1/Step4/Q2_R1__Guideline.pdf (accessed September 5, 2016).
  • [34] Reviewer Guidance, Validation of Chromatographic Methods, Center for Drug Evaluation and Research, US Food and Drug Administration, 1994, http://www.fda.gov/downloads/drugs/guidances/ucm134409.pdf (accessed September 21, 2016). Google Scholar
  • [35] Shabir G. A. J. Chromatogr. A 2003, 987, 57–66.
Uwagi
PL
Opracowanie rekordu w ramach umowy 509/P-DUN/2018 ze środków MNiSW przeznaczonych na działalność upowszechniającą naukę (2018).
Typ dokumentu
Bibliografia
Identyfikator YADDA
bwmeta1.element.baztech-8d3bcb95-34c3-4b72-8a1c-d4fe9eabca82
JavaScript jest wyłączony w Twojej przeglądarce internetowej. Włącz go, a następnie odśwież stronę, aby móc w pełni z niej korzystać.